Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $83.51 million. The enterprise value is -$145.40 million.
Important Dates
The next estimated earnings date is Tuesday, March 25, 2025, before market open.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 60.08 million shares outstanding. The number of shares has increased by 34.18% in one year.
| Current Share Class | 60.08M |
| Shares Outstanding | 60.08M |
| Shares Change (YoY) | +34.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 15.46% |
| Owned by Institutions (%) | 41.64% |
| Float | 32.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.43, with a Debt / Equity ratio of 0.14.
| Current Ratio | 10.43 |
| Quick Ratio | 10.08 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.72 |
Financial Efficiency
Return on equity (ROE) is -32.83% and return on invested capital (ROIC) is -22.02%.
| Return on Equity (ROE) | -32.83% |
| Return on Assets (ROA) | -20.99% |
| Return on Invested Capital (ROIC) | -22.02% |
| Return on Capital Employed (ROCE) | -37.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | 414.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.13% in the last 52 weeks. The beta is -0.01, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -58.13% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 37.15 |
| Average Volume (20 Days) | 232,872 |
Short Selling Information
The latest short interest is 1.84 million, so 3.06% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 1.83M |
| Short % of Shares Out | 3.06% |
| Short % of Float | 5.70% |
| Short Ratio (days to cover) | 5.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | -43.56M |
| Operating Income | -92.91M |
| Pretax Income | -55.94M |
| Net Income | -81.67M |
| EBITDA | -92.84M |
| EBIT | -92.91M |
| Earnings Per Share (EPS) | -$1.37 |
Full Income StatementBalance Sheet
The company has $200.34 million in cash and $29.99 million in debt, giving a net cash position of $228.91 million or $3.81 per share.
| Cash & Cash Equivalents | 200.34M |
| Total Debt | 29.99M |
| Net Cash | 228.91M |
| Net Cash Per Share | $3.81 |
| Equity (Book Value) | 217.20M |
| Book Value Per Share | 3.62 |
| Working Capital | 187.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$67.31 million and capital expenditures -$30,000, giving a free cash flow of -$67.34 million.
| Operating Cash Flow | -67.31M |
| Capital Expenditures | -30,000 |
| Free Cash Flow | -67.34M |
| FCF Per Share | -$1.12 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |